3:38 PM
 | 
Jan 09, 2019
 |  BC Extra  |  Clinical News

Opdivo meets OS endpoint in esophageal cancer trial

Ono Pharmaceutical Co. Ltd. (Tokyo:4528) said anti-PD-1 mAb Opdivo nivolumab met the primary endpoint vs. chemotherapy of improving overall survival in the Phase III ATTRACTION-3 trial...

Read the full 110 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >